150 mg mL −1 , 25 °C, pH 7
The Applicant performed a pivotal comparative bioavailability study using a single 600
For oral drugs where reductions in bioavailability may cause clinically significant effects
1055/s-0035-1555784 Background: Post-menopausal women
Study 140161 is a pivotal 3-way crossover relative bioavailability study of Background: Levothyroxine (LT4) sodium is a standard treatment for hypothyroidism
Grapefruit juice may also delay the absorption of levothyroxine and reduce its bioavailability
Intestinal absorption may be This study has been conducted to compare the bioavailability of levothyroxine oral solution and levothyroxine soft-gel capsule under fasting conditions
5 or 25 mcg daily at intervals of 1–2 weeks until desired response is obtained
In this review, we first summarize the medical conditions that interfere with the bioavailability of oral levothyroxine and discuss the underlying mechanisms and treatments
Based on medical practice, the relative bioavailability between oral and intravenous administration of Levothyroxine Sodium for Injection is estimated to be from 48 to 74%
2 (33); 95% confidence interval (CI) 76 to 108
the IV dose of a drug with poor oral bioavailability can be just a fraction of the PO dose
In addition, many drugs and foods affect T4 absorption [see Drug Interactions (7)]
The bioavailability of LT4 is about 70% following an oral dose, with absorption occurring
The bioavailability of oral levothyroxine is about 60 to 80% in euthyroid patients, and increases in patients with hypothyroidism; the bioavailability of IV levothyroxine is, by definition, 100%
Oral levothyroxine (LT4) is the standard therapy for patients with hypothyroidism
Bioequivalence studies are the most widely used method to demonstrate interchangeability, although controversy persists regarding the best design for this
The relative bioavailability between oral and IV levothyroxine is estimated to be from 48% to 74%, therefore a dosage reduction is required when giving IV replacement therapy